Literature DB >> 29916184

Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells.

Hilary A Seifert1,2, Gil Benedek1,2,3, Ha Nguyen1,2, Grant Gerstner1,2, Ying Zhang1,2, Gail Kent1,2, Arthur A Vandenbark1,2,4, Jürgen Bernhagen5,6, Halina Offner7,8,9.   

Abstract

A seven day pretreatment course of an oral antibiotic cocktail (Ampicillin, Metronidazole, Neomycin Sulfate, and Vancomycin) was shown to induce changes in peripheral immune regulation and protect mice from signs of experimental autoimmune encephalomyelitis (EAE). To determine if a shorter course of antibiotic pretreatment could also protect the mice from EAE and induce regulatory immune cells, studies were conducted using the same oral antibiotic cocktail for three days. In addition, the CNS was examined to determine the effects of antibiotic pretreatment on EAE disease course and immune modulation within the affected tissue. The shorter three day pretreatment course was also significantly protective against severe EAE in C57BL/6 mice. Moreover, our study found increased frequencies of regulatory cells and a decrease in the frequency of anti-inflammatory macrophages in the spleen of EAE protected mice. Additionally, a chemokine and chemokine receptor array run on mRNA from spinal cords revealed that genes associated with regulatory T cells and macrophage recruitment were strongly upregulated in the antibiotic pretreated mice. Additional RT-PCR data showed genes associated with anti-inflammatory microglia/macrophages were upregulated and pro-inflammatory genes were downregulated. This suggests the macrophages recruited to the spinal cord by chemokines are subsequently polarized toward an anti-inflammatory phenotype. These results lend strong support to the conclusion that a three day course of antibiotic treatment given prior to the induction of severe EAE profoundly protected the mice by inducing regulatory lymphocytes in the periphery and an anti-inflammatory milieu in the affected spinal cord tissue.

Entities:  

Keywords:  Antibiotic; CNS; EAE; Microbiota; Neuroinflammation; Regulatory cells

Mesh:

Substances:

Year:  2018        PMID: 29916184      PMCID: PMC6298859          DOI: 10.1007/s11011-018-0266-7

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A commensal bacterial product elicits and modulates migratory capacity of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflammation.

Authors:  Yan Wang; Sakhina Begum-Haque; Kiel M Telesford; Javier Ochoa-Repáraz; Marc Christy; Eli J Kasper; Dennis L Kasper; Simon C Robson; Lloyd H Kasper
Journal:  Gut Microbes       Date:  2014-07-09

3.  Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.

Authors:  Kerstin Berer; Marsilius Mues; Michail Koutrolos; Zakeya Al Rasbi; Marina Boziki; Caroline Johner; Hartmut Wekerle; Gurumoorthy Krishnamoorthy
Journal:  Nature       Date:  2011-10-26       Impact factor: 49.962

4.  Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice.

Authors:  Jun Zhang; Andrew Lapato; Sheetal Bodhankar; Arthur A Vandenbark; Halina Offner
Journal:  Metab Brain Dis       Date:  2015-03-18       Impact factor: 3.584

5.  Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis.

Authors:  Yun Kyung Lee; Juscilene S Menezes; Yoshinori Umesaki; Sarkis K Mazmanian
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

6.  Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells.

Authors:  Hyung W Lim; Jeeho Lee; Peter Hillsamer; Chang H Kim
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

7.  IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production.

Authors:  Jinbo Liu; Feng Lin; Michael G Strainic; Fengqi An; Robert H Miller; Cengiz Z Altuntas; Peter S Heeger; Vincent K Tuohy; M Edward Medof
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

8.  Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes.

Authors:  Mohammad Fararjeh; Mohammad K Mohammad; Yasser Bustanji; Hatim Alkhatib; Shtaywy Abdalla
Journal:  Int Immunopharmacol       Date:  2007-11-20       Impact factor: 4.932

9.  CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.

Authors:  Markus C Kowarik; Sabine Cepok; Johann Sellner; Verena Grummel; Martin S Weber; Thomas Korn; Achim Berthele; Bernhard Hemmer
Journal:  J Neuroinflammation       Date:  2012-05-16       Impact factor: 8.322

10.  CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells.

Authors:  Moran Meiron; Yaniv Zohar; Rachel Anunu; Gizi Wildbaum; Nathan Karin
Journal:  J Exp Med       Date:  2008-10-13       Impact factor: 14.307

View more
  9 in total

Review 1.  Mini-Review: Gut-Microbiota and the Sex-Bias in Autoimmunity - Lessons Learnt From Animal Models.

Authors:  Elizabeth C Rosser; Nina M de Gruijter; Diana E Matei
Journal:  Front Med (Lausanne)       Date:  2022-06-16

2.  Effects of Vancomycin on Persistent Pain-Stimulated and Pain-Depressed Behaviors in Female Fischer Rats With or Without Voluntary Access to Running Wheels.

Authors:  Emily Payne; Kylee Harrington; Philomena Richard; Rebecca Brackin; Ravin Davis; Sarah Couture; Jacob Liff; Francesca Asmus; Elizabeth Mutina; Anyssa Fisher; Denise Giuvelis; Sebastien Sannajust; Bahman Rostama; Tamara King; Lisa M Mattei; Jung-Jin Lee; Elliot S Friedman; Kyle Bittinger; Meghan May; Glenn W Stevenson
Journal:  J Pain       Date:  2021-05-21       Impact factor: 5.820

3.  Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors.

Authors:  Carlos G Gonzalez; Stephanie K Tankou; Laura M Cox; Ellen P Casavant; Howard L Weiner; Joshua E Elias
Journal:  Sci Rep       Date:  2019-08-28       Impact factor: 4.379

4.  Antibiotic-modulated microbiome suppresses lethal inflammation and prolongs lifespan in Treg-deficient mice.

Authors:  Baokun He; Yuying Liu; Thomas K Hoang; Xiangjun Tian; Christopher M Taylor; Meng Luo; Dat Q Tran; Nina Tatevian; J Marc Rhoads
Journal:  Microbiome       Date:  2019-11-07       Impact factor: 14.650

Review 5.  Major histocompatibility complex Class II-based therapy for stroke.

Authors:  Bella M Gonzales-Portillo; Jea-Young Lee; Arthur A Vandenbark; Halina Offner; Cesario V Borlongan
Journal:  Brain Circ       Date:  2021-03-30

Review 6.  ILC3, a Central Innate Immune Component of the Gut-Brain Axis in Multiple Sclerosis.

Authors:  Đorđe Miljković; Bojan Jevtić; Ivana Stojanović; Mirjana Dimitrijević
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

Review 7.  Sepsis and multiple sclerosis: Causative links and outcomes.

Authors:  Đorđe Miljković; Suzana Stanisavljević; Isaac J Jensen; Thomas S Griffith; Vladimir P Badovinac
Journal:  Immunol Lett       Date:  2021-07-25       Impact factor: 4.230

8.  Perturbation of gut microbiota decreases susceptibility but does not modulate ongoing autoimmune neurological disease.

Authors:  Clemens Gödel; Birgit Kunkel; Alireza Kashani; Hans Lassmann; Manimozhiyan Arumugam; Gurumoorthy Krishnamoorthy
Journal:  J Neuroinflammation       Date:  2020-03-06       Impact factor: 8.322

Review 9.  Intestinal Dysbiosis and Tryptophan Metabolism in Autoimmunity.

Authors:  Josephine Brown; Brian Robusto; Laurence Morel
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.